{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:25:03Z","timestamp":1792445103411,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01457-3","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:10:56Z","timestamp":1774275056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3011-7747","authenticated-orcid":false,"given":"Matthew","family":"Hamby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-799X","authenticated-orcid":false,"given":"Brian L.","family":"Egleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A. K.","family":"Frosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael E.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-5367","authenticated-orcid":false,"given":"Emeline R.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda S.","family":"Tolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-6542","authenticated-orcid":false,"given":"Gaston","family":"Jean-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-6454","authenticated-orcid":false,"given":"Timothy","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ramirez-Gamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hamburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dittus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A.","family":"Nizamuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyein Nyein","family":"Thaw Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sandoval-Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Rojek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufer","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Solipuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-461X","authenticated-orcid":false,"given":"Paul G.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Suneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Vartanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Milrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Smilnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-4507","authenticated-orcid":false,"given":"Emily","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahaj","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Magarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Pellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Aboulafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineel","family":"Bhatlapenumarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"1457_CR1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413\u201320.","journal-title":"Blood"},{"key":"1457_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","volume":"38","author":"J Morscio","year":"2014","unstructured":"Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38:875\u201386.","journal-title":"Am J Surg Pathol"},{"key":"1457_CR3","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","volume":"125","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323\u201330.","journal-title":"Blood"},{"key":"1457_CR4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/modpathol.3800355","volume":"18","author":"F Vega","year":"2005","unstructured":"Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806\u201315.","journal-title":"Mod Pathol"},{"key":"1457_CR5","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/j.clml.2023.12.014","volume":"24","author":"AR Hansen","year":"2024","unstructured":"Hansen AR, Vardell VA, Fitzgerald LA. Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the United States: a SEER and NCDB analysis. Clin Lymphoma Myeloma Leuk. 2024;24:e152\u2013160.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1457_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mdw684","volume":"28","author":"E Tchernonog","year":"2017","unstructured":"Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Genin M, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28:843\u20138.","journal-title":"Ann Oncol"},{"key":"1457_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15156","volume":"184","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184:679\u201382.","journal-title":"Br J Haematol"},{"key":"1457_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","volume":"15","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15:293\u20139.","journal-title":"Oncologist"},{"key":"1457_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood-2024-211388","volume":"144","author":"A Noy","year":"2024","unstructured":"Noy A, Barta SK, Kwon D, Baiocchi R, Ramos JC, Rubinstein P, et al. Daratumumab with dose-adjusted EPOCH is feasible in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105. Blood. 2024;144:870.","journal-title":"Blood"},{"key":"1457_CR10","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.3390\/jcm11164928","volume":"11","author":"YK Ryu","year":"2022","unstructured":"Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma. J Clin Med. 2022;11:4928.","journal-title":"J Clin Med"},{"key":"1457_CR11","unstructured":"NCCN guidelines version 3.2024. HIV-related B-cell lymphomas. Accessed October 17, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"1457_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.2023021348","volume":"143","author":"PR Di Ciaccio","year":"2024","unstructured":"Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, et al. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2024;143:152\u201365.","journal-title":"Blood"},{"key":"1457_CR13","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1002\/cncr.27551","volume":"118","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Beltr\u00e1n BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118:5270\u20137.","journal-title":"Cancer"},{"key":"1457_CR14","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. IARC; 2017."},{"key":"1457_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","volume":"9","author":"DF McCaffrey","year":"2004","unstructured":"McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9:403\u201325.","journal-title":"Psychol Methods"},{"key":"1457_CR16","unstructured":"Ridgeway G, McCaffrey D, Morral A, Cefalu M, Burgette L, Pane J, et al. Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial for the Twang Package."},{"key":"1457_CR17","first-page":"85","volume":"27","author":"TE Raghunathan","year":"2001","unstructured":"Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol. 2001;27:85\u201395.","journal-title":"Surv Methodol"},{"key":"1457_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project.","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"1457_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjh.18399","volume":"199","author":"R Jessa","year":"2022","unstructured":"Jessa R, Chien N, Villa D, Freeman CL, Slack GW, Savage KJ, et al. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. Br J Haematol. 2022;199:230\u20138.","journal-title":"Br J Haematol"},{"key":"1457_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0327-0","volume":"10","author":"HM Witte","year":"2020","unstructured":"Witte HM, Hertel N, Merz H, Bernd HW, Bernard V, Stolting S, et al. Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multicenter study of 76 consecutive patients. Blood Cancer J. 2020;10:63.","journal-title":"Blood Cancer J"},{"key":"1457_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood.2022016534","volume":"141","author":"N Thomas","year":"2023","unstructured":"Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141:904\u201316.","journal-title":"Blood"},{"key":"1457_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.26744","volume":"98","author":"C Radkiewicz","year":"2023","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, et al. Sex differences in lymphoma incidence and mortality by subtype: a population-based study. Am J Hematol. 2023;98:23\u201330.","journal-title":"Am J Hematol"},{"key":"1457_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/EDBK_175447","volume":"37","author":"M Pfreundschuh","year":"2017","unstructured":"Pfreundschuh M. Age and sex in non-Hodgkin lymphoma therapy: it\u2019s not all created equal, or is it? Am Soc Clin Oncol Educ Book. 2017;37:505\u201311.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1457_CR24","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","volume":"122","author":"SK Barta","year":"2013","unstructured":"Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251\u201362.","journal-title":"Blood"},{"key":"1457_CR25","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2019-129702","volume":"134","author":"CR Tan","year":"2019","unstructured":"Tan CR, Barta SK, Lensing SY, Noy A. A multicenter, open-label feasibility study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma with or without HIV. Blood. 2019;134:1595.","journal-title":"Blood"},{"key":"1457_CR26","unstructured":"Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients, NCT04915248."},{"key":"1457_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","volume":"133","author":"M Klanova","year":"2019","unstructured":"Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133:919\u201326.","journal-title":"Blood"},{"key":"1457_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.2021012888","volume":"139","author":"VM Orellana-Noia","year":"2022","unstructured":"Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139:413\u201323.","journal-title":"Blood"},{"key":"1457_CR29","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/bjh.18228","volume":"198","author":"C Dittus","year":"2022","unstructured":"Dittus C, Miller JA, Wehbie R, Castillo JJ. Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. Br J Haematol. 2022;198:e32\u2013e34.","journal-title":"Br J Haematol"},{"key":"1457_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702593","volume":"12","author":"L Cheng","year":"2021","unstructured":"Cheng L, Song Q, Liu M, Wang Y, Yi H, Qian Y, et al. Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide. Front Immunol. 2021;12:702593.","journal-title":"Front Immunol"},{"key":"1457_CR31","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.clml.2018.04.011","volume":"18","author":"WD Marrero","year":"2018","unstructured":"Marrero WD, Cruz-Chacon A, Castillo C, Cabanillas F. Successful use of bortezomib-lenalidomide combination as treatment for a patient with plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:e275\u2013e277.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1457_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000504608","volume":"43","author":"K Ando","year":"2020","unstructured":"Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, et al. Bortezomib- and lenalidomide-based treatment of refractory plasmablastic lymphoma. Oncol Res Treat. 2020;43:112\u20136.","journal-title":"Oncol Res Treat"},{"key":"1457_CR33","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1002\/ajh.25682","volume":"95","author":"R Raychaudhuri","year":"2020","unstructured":"Raychaudhuri R, Qualtieri J, Garfall AL. Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. Am J Hematol. 2020;95:E28\u2013E30.","journal-title":"Am J Hematol"},{"key":"1457_CR34","doi-asserted-by":"publisher","first-page":"e006684","DOI":"10.1136\/jitc-2023-006684","volume":"11","author":"S Raghunandan","year":"2023","unstructured":"Raghunandan S, Pauly M, Blum WG, Qayed M, Dhodapkar MV, Elkhalifa M, et al. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. J Immunother Cancer. 2023;11:e006684.","journal-title":"J Immunother Cancer"},{"key":"1457_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104551","volume":"205","author":"S Feng","year":"2025","unstructured":"Feng S, Xiong Y, Liu W, Liu H, Sui W, Zheng P, et al. BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: case report and literature review. Crit Rev Oncol Hematol. 2025;205:104551.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01457-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:36:49Z","timestamp":1774593409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01457-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01457-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7607922\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}